title: Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
abstract: OBJECTIVE
  To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe.
  
  
  METHODS
  Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined.
  
  
  RESULTS
  Oritavancin was very active against MRSA (MIC(50)/MIC(90) 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis).
  
  
  CONCLUSIONS
  These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.
authors.affiliation: Quotient Bioresearch Ltd, Fordham, UK. imorrissey@ihmainc.com
authors.forename: Ian
authors.initials: I
authors.lastname: Morrissey
authors.forename: Harald
authors.initials: H
authors.lastname: Seifert
authors.forename: Rafael
authors.initials: R
authors.lastname: Canton
authors.forename: Patrice
authors.initials: P
authors.lastname: Nordmann
authors.forename: Stefania
authors.initials: S
authors.lastname: Stefani
authors.forename: Alasdair
authors.initials: A
authors.lastname: Macgowan
authors.forename: Regina
authors.initials: R
authors.lastname: Janes
authors.forename: Daniel
authors.initials: D
authors.lastname: Knight
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016983:Enterococcus / Q000187:drug effects* / Q000254:growth & development; D005060:Europe / Q000453:epidemiology; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance / Q000187:drug effects* / Q000502:physiology; D008826:Microbial Sensitivity Tests / Q000379:methods; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development; D013291:Streptococcus / Q000187:drug effects* / Q000254:growth & development; D014640:Vancomycin / Q000494:pharmacology / Q000031:analogs & derivatives; D020713:Vancomycin Resistance / Q000187:drug effects* / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014640:Vancomycin; C100708:oritavancin